{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Acute Graft-versus-Host-Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Chronic extensive Graft-versus-Host-Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"aGVHD The diagnosis of aGVHD is identified through various stages and grading of the disease related to Skin (Rash), Gut (Diarrhea, Nausea/vomiting and/or anorexia) and the liver (Bilirubin) assessed by severity and grading scale outlined in the section Grafts vs Hosts by Sullivan (1999).\n\nGVHD Grades Grade I: 1-2 Skin Rash; No gut or liver involvement Grade II: Stage 1-3 Skin rash; Stage 1 gut and/or stage 1 liver involvement Grade III: Stage 2-4 gut involvement and/or stage 2-4 liver involvement with or without rash Grade IV: Pattern and severity of GVHD similar to grade 3 with extreme constitutional symptoms or death\n\nCGVHD The diagnosis of cGVHD requires at least one manifestation that is distinctive for chronic GVHD as opposed to acute GVHD. In all cases, infection and others causes must be ruled out in the differential diagnosis of chronic GVHD.","groups":[{"description":"Allogeneic Bone Marrow Transplantation: Undergo donor HCT\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo donor HCT\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo autologous PBSC transplant\n\nAutologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation: Undergo autologous-donor tandem HCT\n\nCarmustine: Given IV\n\nCyclophosphamide: Given IV\n\nCytarabine: Given IV\n\nEtoposide: Given IV\n\nFludarabine Phosphate: Given IV\n\nLaboratory Biomarker Analysis: Correlative study\n\nMelphalan: Given IV\n\nMycophenolate Mofetil: Given PO\n\nPeripheral Blood Stem Cell Transplantation: Undergo donor HCT\n\nTacrolimus: Given IV or PO\n\nTotal-Body Irradiation: Undergo TBI","id":"OG000","title":"Treatment (Autologous HCT, Donor HCT)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Two patients are not evaluable for Graft-versus-Host-Disease due to disease progression; they failed the study and did not receive the allogeneic transplantation.","reportingStatus":"POSTED","timeFrame":"1 year post-allograft,","title":"Number of Patients With Grade II-IV Acute Graft-versus-Host-Disease and/or Chronic Extensive Graft-versus-Host-Disease","type":"SECONDARY","unitOfMeasure":"Participants"}